Hello, this is Daily Stock, analyzing structural changes in global equity markets and Nasdaq growth stocks.
[Image: /stdaily/uploads/202609/gen_6aab2da83d1375.41240614.png]
Key Summary
Vertex Pharmaceuticals (VRTX)'s 'CASGEVY', the world's first CRISPR gene-editing therapy, has moved past early launch delay concerns and entered an active revenue ramp-up phase.
After lingering around $10 million in 2024, Casgevy revenue surged to $115.8 million in 2025. Moving into 2026, it has become a central driver in meeting the company's guidance of generating over $500 million annually from its non-cystic fibrosis (non-CF) portfolio.
The 4-to-6 month patient journey—encompassing cell collection, pre-treatment conditioning, gene editing, and infusion—has been accumulating as leading indicators, significantly improving revenue visibility.
Robust free cash flow (FCF) anchored by cystic fibrosis (CF) treatments is expanding into gene editing, non-opioid pain management (JOURNAVX), and kidney diseases, positioning the stock as a stable growth alternative amid Big Tech AI CAPEX fatigue.
Current Market Context
As of intraday trading in the Korean market on September 17, 2026 (preliminary), U.S. equities are experiencing heightened volatility driven by macro uncertainties and debates surrounding the timing of Big Tech AI monetization.
According to Daily Stock's proprietary Fear & Greed Index, the Nasdaq is currently in 'Fear' territory at 26.5, cooling sharply compared to 'Fear' (38.2) a week ago, 'Greed' (64.3) a month ago, and 'Greed' (64.4) three months ago.
Domestically, the KOSPI Fear & Greed Index also retreated to 'Fear' (31.3) from 'Neutral' (47) a week ago and 'Neutral' (56.6) a month ago. Intraday levels (preliminary) stand at KOSPI 6,777.29, KOSDAQ 820.38, and USD/KRW at 1,378.00.
Amid this multiple compression across major benchmark indices, Nasdaq large-cap biotech Vertex is displaying strong downside price resilience around the $513–$515 level (latest verified level, pending regular session quotes).
Casgevy has effectively cleared prescription bottlenecks for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) by significantly expanding global Authorized Treatment Centers (ATCs) and securing over 90% reimbursement coverage in the United States.
[Image: /stdaily/uploads/202609/gen_6aab2db23620e6.61482728.png]
Financial Analysis
Vertex posted Q2 2026 revenue of $3.33 billion, sustaining robust year-over-year growth of 12%.
The company raised its full-year 2026 revenue guidance from the previous range of $12.95B–$13.1B to $13.1B–$13.2B.
| Metric | 2024 Actual | 2025 Actual | 2026 Annual Guidance |
|---|---|---|---|
| Total Revenue | $11.02B | $12.00B | $13.10B – $13.20B |
| YoY Growth Rate | +12% | +9% | +9.2% – +10.0% |
| CASGEVY Revenue | Approx. $10M | $115.8M | Driving >$500M in non-CF segment |
| Cash & Short-Term Investments | Approx. $11.2B | Approx. $12.5B | Reflecting pending $10B Crinetics acquisition |
| Primary Cash Cow | Trikafta-led CF franchise | Trikafta / Alyftrek | Next-gen CF triple combination + pipeline |
Source: Compiled from Vertex Pharmaceuticals regulatory filings
The core financial driver is the accelerated quarterly revenue recognition resulting from stabilized manufacturing workflows for Casgevy.
After showing gradual growth—from $8 million in Q4 2024 to $54.8 million in Q4 2025—the trend has translated into an over 150% year-over-year increase in procedure volumes entering 2026.
Under the 60:40 net profit and loss sharing agreement with co-developer CRISPR Therapeutics (60% Vertex, 40% CRISPR), marketing and manufacturing optimization costs are also stabilizing each quarter.
Valuation
Vertex has historically traded at a discount reflecting single-disease dependence due to its cystic fibrosis monopoly.
Currently trading at a forward P/E in the mid-to-high 20s, the company has seen some near-term EPS fluctuations caused by non-cash amortization and R&D expenses associated with its $10 billion acquisition of Crinetics, but its core cash-generating power remains fully intact.
Unlike Big Tech firms undertaking colossal capital expenditures (CAPEX) for AI data centers and facing FCF contraction risks, Vertex self-funds large-scale clinical trials and pipeline acquisitions entirely through operating cash flow.
Despite swings in the 10-year Treasury yield (US10Y) and the U.S. Dollar Index (DXY), Vertex demonstrates multiple resilience thanks to inelastic drug demand and the high barrier to entry inherent in its one-time gene therapy platform.
When valuation strain builds on large-cap software and semiconductor stocks within the Nasdaq-100, large-cap biotechs with validated clinical milestones and commercial execution offer an appealing hedge during periods of elevated volatility (VIX).
Expert & Institutional Perspectives
Leading Wall Street investment banks are reframing Casgevy's revenue recognition model through the lens of long-term recurring cash flows.
The full journey—from patient onboarding and hematopoietic stem cell collection at an ATC, to external CRISPR editing, pre-transplant conditioning chemotherapy, and final infusion—typically spans several months.
Analysts emphasize that the roughly 300 treatment initiations started in the second half of 2025 are systematically converting into reported revenue throughout 2026.
Major institutions, including Morgan Stanley and Jefferies, project Casgevy will reach blockbuster status (annual revenue exceeding $1 billion) around 2028 on a standalone basis.
Furthermore, recent label expansion approvals for pediatric patients (ages 2 and up) and progress on government reimbursement agreements across Europe and the Middle East represent pivotal catalysts that substantially broaden the long-term total addressable market (TAM).
[Image: /stdaily/uploads/202609/gen_6aab2dbd10a4a7.45257987.png]
Risk Factors
The primary risk is the logistical and manufacturing turnaround-time bottleneck characteristic of cell therapies.
Because Casgevy is an autologous treatment tailored individually from a patient's own cells, manufacturing yield defects or contamination inevitably cause scheduling delays.
A second consideration is the burden of myeloablative chemotherapy pre-conditioning (busulfan conditioning).
Risks such as potential infertility or severe infection associated with conditioning lead some patients with milder symptoms to defer treatment initiation.
From a macroeconomic perspective, any delays in central bank rate cuts could apply broader valuation multiple pressure on the biotech sector via higher capital costs, while U.S. drug pricing regulations remain an ongoing headwind.
Investment Takeaways
Vertex is no longer a conventional pharmaceutical company confined to a single cystic fibrosis pipeline.
The commercial scaling of Casgevy represents more than top-line numbers; it validates the company's ability to take a brand-new therapeutic modality from clinical proof-of-concept through global regulatory clearance and full-scale commercialization.
With non-opioid pain candidate JOURNAVX carving out its market presence, FDA review outcomes on the horizon for IgA nephropathy candidate povetacicept, and an expansion into rare endocrine disorders via the Crinetics acquisition, Vertex's portfolio diversification is moving in sync.
With the Nasdaq Fear & Greed Index deep in 'Fear' at 26.5, allocating capital toward large-cap healthcare growth names with established cash flow and proven clinical execution can serve as a compelling strategy over short-term tech momentum.
Investor Checkpoint Q&A
Q1. What provides high visibility into Casgevy's sharp revenue acceleration in 2026?
Casgevy requires several months from cell harvesting to final infusion. Over 300 patients entered the treatment pathway and more than 150 completed cell collection in 2025, providing upfront visibility into the volume of infusions and recognized revenue scheduled across the first and second halves of 2026.
Q2. What is the per-patient treatment cost, and what does reimbursement look like?
In the United States, Casgevy carries a list price of approximately $2.2 million per treatment. Given the severity of the diseases it treats, roughly 90% of eligible U.S. patients have secured public or commercial insurance coverage, while reimbursement agreements are steadily closing across more than 10 global markets, including the UK and Saudi Arabia.
Q3. How does the profit-sharing structure work with CRISPR Therapeutics (CRSP)?
Vertex and CRISPR Therapeutics share worldwide net profits and losses on a 60:40 basis. Vertex leads global commercial infrastructure and distribution, and pays 40% of net profits to its partner after settling shared R&D and commercialization expenses.
Q4. What is the strategic rationale behind the $10 billion acquisition of Crinetics?
The acquisition aims to build rare endocrine diseases into Vertex's fifth core business pillar, reducing portfolio concentration in cystic fibrosis. By acquiring commercialized assets and promising Phase 3 candidates simultaneously, Vertex is positioning itself for sustained mid-to-long-term top-line expansion beyond 2027.
Q5. What are the advantages of adding Vertex over traditional Nasdaq tech stocks?
Vertex is fundamentally insulated from the heavy CAPEX spending required for AI infrastructure and corporate IT budget cuts caused by broader economic slowdowns. Supported by strong, self-funding FCF, Vertex offers the defensive growth profile of sustainable double-digit revenue expansion even amid high interest rates or macroeconomic cooling.